J&J no longer co-promoting Capoten
Bristol-Myers Squibb and Johnson & Johnson's McNeil Pharmaceutical unit agree to discontinue, effective June 21, the co-promotion arrangement covering the ACE inhibitor product. McNeil's 450-rep sales force had been promoting Capoten to primary care physicians since January 1988. Bristol-Myers, which acquired Squibb in 1989, explained that the merger "now enables us to use our own greatly expanded sales force to sell Capoten in the U.S."
You may also be interested in...
ABHI’s Phil Brown believes the future of UK device regulation will be innovation-friendly and patient-responsive system – but doesn’t expect easy alignment with the EU. See what he had to say.
Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.
With the meetings available on television, access can be assured for just about everyone, and the US FDA can avoid another gut punch to its credibility.